CRL 64.43 Charles River Laboratories Intl $CRL Hit a 52 week high of 66.11 Closing the day 11/03/14 at 64.43 +1.27 +2.01% With a day low of 64.05 and a total volume of 991,487.
CRL Recent Posts: http://investorshangout.com/Charles-River-Lab...CRL-50619/
CRL Charles River Laboratories Intl Recent Headline News
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.78 (+0.06), TTWO: 25.83 (-0.62), BIIB: 321.25 (+0.17), GILD: 109.98 (-2.02), CRL: 64.43 (+1.27), REGN: 395.26 (+1.54), CELG: 107.41 (+0.32)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.30 (-0.47), BIIB: 321.25 (+0.17), HON: 95.66 (-0.46), FB: 73.88 (-1.11), BMY: 57.80 (-0.39), MGM: 23.02 (-0.23), ATK: 117.07 (+0.11), YRCW: 22.29 (+0.85), UPS: 105.64 (+0.73), SLB: 96.52 (-2.14), CELG: 107.41 (+0.32), WPRT: 5.97 (-0.20), SBUX: 76.10 (+0.54), TTWO: 25.83 (-0.62), DO: 34.72 (-2.99), ETP: 64.40 (-0.03), GILD: 109.98 (-2.02), ARR: 3.96 (unch), CMG: 638.53 (+0.53), MPEL: 26.57 (-0.57), WNC: 10.14 (-0.16), CRL: 64.43 (+1.27), AAPL: 109.40 (+1.40), REGN: 395.26 (+1.54)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 193.14 (+3.08), ABBV: 63.25 (-0.21), BMY: 57.80 (-0.39), CRL: 64.43 (+1.27)
Charles River Laboratories International In (CRL) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Thu Oct 30, 9:04AM CDT
Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
CRL: 64.43 (+1.27)
Charles River beats Street 3Q forecasts
Automated Insights - Wed Oct 29, 5:45PM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $32 million.
CRL: 64.43 (+1.27)
Ampersand Exits ChanTest Investment
PR Newswire - Wed Oct 29, 3:56PM CDT
Ampersand Capital Partners is pleased to announce the successful sale of Cleveland, Ohio based ChanTest, a leading provider of specialized laboratory testing services for drug development. ChanTest has been acquired by Charles River Laboratories International, Inc. in an all-cash transaction.
CRL: 64.43 (+1.27)
Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations
Business Wire - Wed Oct 29, 3:06PM CDT
--- Third-Quarter GAAP Earnings per Share of $0.68 and Non-GAAP Earnings per Share of $0.86 -
CRL: 64.43 (+1.27)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 193.14 (+3.08), ESRX: 77.10 (+0.28), CAH: 78.58 (+0.10), UNH: 94.86 (-0.15), CRL: 64.43 (+1.27)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 193.14 (+3.08), MCK: 203.39 (-0.02), CAH: 78.58 (+0.10), CRL: 64.43 (+1.27)
Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:01PM CDT
We expect Cigna (CI) to give a positive surprise when it reports its earnings on Oct 30, given its Zacks Rank #3 and a positive Earnings ESP.
CI: 99.73 (+0.16), INFI: 13.25 (-0.37), AMAG: 33.82 (+0.81), CRL: 64.43 (+1.27)
Will PerkinElmer (PKI) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 4:59PM CDT
PerkinElmer (PKI) has managed to perform decently across several product lines and also posted solid operating results in the previous quarter.
HTWR: 77.02 (-0.10), CRL: 64.43 (+1.27), HSIC: 119.71 (-0.32), PKI: 43.81 (+0.39)
Why Earnings Season Could Be Great for Charles River Laboratories International (CRL) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:57AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Charles River Laboratories International may be one such company as the firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report
CRL: 64.43 (+1.27)
Why Charles River Laboratories International (CRL) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:52AM CDT
Charles River Laboratories International could be a great candidate for another beat after a solid performance in the last two quarters.
CRL: 64.43 (+1.27)
Will WellPoint (WLP) Surpass Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:00PM CDT
WellPoint Inc. (WLP) is set to report third-quarter 2014 earnings results on Oct 29, 2014.
MDVN: 105.40 (-0.30), AMSG: 52.41 (-1.60), CRL: 64.43 (+1.27), WLP: 126.31 (-0.38)
Omnicare Beats on Q3 Earnings and Sales, Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:40AM CDT
Omnicare Inc. (OCR) reported better-than-expected third quarter 2014 results.
PMC: 28.26 (-0.43), OCR: 66.54 (-0.05), CRL: 64.43 (+1.27), ICLR: 53.95 (+1.34)
Healthways Earnings and Revenues in Line, View Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 9:10AM CDT
Healthways Inc. (HWAY) affirmed its 2014 financial guidance and expects adjusted earnings in the range of 11 to 26 cents per share for 2014.
BGMD: 0.48 (+0.04), HWAY: 15.15 (-0.35), CRL: 64.43 (+1.27), ICLR: 53.95 (+1.34)
Upgrade Alert for Charles River Laboratories (CRL)
Comtex SmarTrend(R) - Wed Oct 15, 7:09AM CDT
Charles River Laboratories (NYSE:CRL) was upgraded from Neutral to Buy at SunTrust today. The stock closed yesterday at $56.53 on volume of 315,000 shares, below average daily volume of 349,000. Potential upside of 9.7% exists for Charles River Laboratories, based on a current level of $56.53 and analysts' average consensus price target of $62.03. Charles River Laboratories shares should first meet resistance at the 200-day moving average (MA) of $56.84 and find additional resistance at the 50-day MA of $59.24.
CRL: 64.43 (+1.27)
Charles River Laboratories Schedules Third-Quarter 2014 Earnings Release and Conference Call
Business Wire - Wed Oct 08, 3:15PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2014 financial results on Wednesday, October 29th, after the market closes. A conference call has been scheduled to discuss this information on Thursday, October 30th, at 9:00 a.m. ET.
CRL: 64.43 (+1.27)
Shares of CRL Up 10.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 19, 11:18AM CDT
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on June 5th, 2014 at $55.08. In approximately 4 months, Charles River Laboratories has returned 10.89% as of today's recent price of $61.08.
CRL: 64.43 (+1.27)
Shares of CRL Up 9.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 12, 10:06AM CDT
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on June 5th, 2014 at $55.08. In approximately 3 months, Charles River Laboratories has returned 9.82% as of today's recent price of $60.49.
CRL: 64.43 (+1.27)
CRL Recent Posts: http://investorshangout.com/Charles-River-Lab...CRL-50619/
CRL Charles River Laboratories Intl Recent Headline News
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.78 (+0.06), TTWO: 25.83 (-0.62), BIIB: 321.25 (+0.17), GILD: 109.98 (-2.02), CRL: 64.43 (+1.27), REGN: 395.26 (+1.54), CELG: 107.41 (+0.32)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.30 (-0.47), BIIB: 321.25 (+0.17), HON: 95.66 (-0.46), FB: 73.88 (-1.11), BMY: 57.80 (-0.39), MGM: 23.02 (-0.23), ATK: 117.07 (+0.11), YRCW: 22.29 (+0.85), UPS: 105.64 (+0.73), SLB: 96.52 (-2.14), CELG: 107.41 (+0.32), WPRT: 5.97 (-0.20), SBUX: 76.10 (+0.54), TTWO: 25.83 (-0.62), DO: 34.72 (-2.99), ETP: 64.40 (-0.03), GILD: 109.98 (-2.02), ARR: 3.96 (unch), CMG: 638.53 (+0.53), MPEL: 26.57 (-0.57), WNC: 10.14 (-0.16), CRL: 64.43 (+1.27), AAPL: 109.40 (+1.40), REGN: 395.26 (+1.54)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 193.14 (+3.08), ABBV: 63.25 (-0.21), BMY: 57.80 (-0.39), CRL: 64.43 (+1.27)
Charles River Laboratories International In (CRL) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Thu Oct 30, 9:04AM CDT
Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
CRL: 64.43 (+1.27)
Charles River beats Street 3Q forecasts
Automated Insights - Wed Oct 29, 5:45PM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $32 million.
CRL: 64.43 (+1.27)
Ampersand Exits ChanTest Investment
PR Newswire - Wed Oct 29, 3:56PM CDT
Ampersand Capital Partners is pleased to announce the successful sale of Cleveland, Ohio based ChanTest, a leading provider of specialized laboratory testing services for drug development. ChanTest has been acquired by Charles River Laboratories International, Inc. in an all-cash transaction.
CRL: 64.43 (+1.27)
Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations
Business Wire - Wed Oct 29, 3:06PM CDT
--- Third-Quarter GAAP Earnings per Share of $0.68 and Non-GAAP Earnings per Share of $0.86 -
CRL: 64.43 (+1.27)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 193.14 (+3.08), ESRX: 77.10 (+0.28), CAH: 78.58 (+0.10), UNH: 94.86 (-0.15), CRL: 64.43 (+1.27)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 193.14 (+3.08), MCK: 203.39 (-0.02), CAH: 78.58 (+0.10), CRL: 64.43 (+1.27)
Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:01PM CDT
We expect Cigna (CI) to give a positive surprise when it reports its earnings on Oct 30, given its Zacks Rank #3 and a positive Earnings ESP.
CI: 99.73 (+0.16), INFI: 13.25 (-0.37), AMAG: 33.82 (+0.81), CRL: 64.43 (+1.27)
Will PerkinElmer (PKI) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 4:59PM CDT
PerkinElmer (PKI) has managed to perform decently across several product lines and also posted solid operating results in the previous quarter.
HTWR: 77.02 (-0.10), CRL: 64.43 (+1.27), HSIC: 119.71 (-0.32), PKI: 43.81 (+0.39)
Why Earnings Season Could Be Great for Charles River Laboratories International (CRL) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:57AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Charles River Laboratories International may be one such company as the firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report
CRL: 64.43 (+1.27)
Why Charles River Laboratories International (CRL) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:52AM CDT
Charles River Laboratories International could be a great candidate for another beat after a solid performance in the last two quarters.
CRL: 64.43 (+1.27)
Will WellPoint (WLP) Surpass Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:00PM CDT
WellPoint Inc. (WLP) is set to report third-quarter 2014 earnings results on Oct 29, 2014.
MDVN: 105.40 (-0.30), AMSG: 52.41 (-1.60), CRL: 64.43 (+1.27), WLP: 126.31 (-0.38)
Omnicare Beats on Q3 Earnings and Sales, Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:40AM CDT
Omnicare Inc. (OCR) reported better-than-expected third quarter 2014 results.
PMC: 28.26 (-0.43), OCR: 66.54 (-0.05), CRL: 64.43 (+1.27), ICLR: 53.95 (+1.34)
Healthways Earnings and Revenues in Line, View Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 9:10AM CDT
Healthways Inc. (HWAY) affirmed its 2014 financial guidance and expects adjusted earnings in the range of 11 to 26 cents per share for 2014.
BGMD: 0.48 (+0.04), HWAY: 15.15 (-0.35), CRL: 64.43 (+1.27), ICLR: 53.95 (+1.34)
Upgrade Alert for Charles River Laboratories (CRL)
Comtex SmarTrend(R) - Wed Oct 15, 7:09AM CDT
Charles River Laboratories (NYSE:CRL) was upgraded from Neutral to Buy at SunTrust today. The stock closed yesterday at $56.53 on volume of 315,000 shares, below average daily volume of 349,000. Potential upside of 9.7% exists for Charles River Laboratories, based on a current level of $56.53 and analysts' average consensus price target of $62.03. Charles River Laboratories shares should first meet resistance at the 200-day moving average (MA) of $56.84 and find additional resistance at the 50-day MA of $59.24.
CRL: 64.43 (+1.27)
Charles River Laboratories Schedules Third-Quarter 2014 Earnings Release and Conference Call
Business Wire - Wed Oct 08, 3:15PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2014 financial results on Wednesday, October 29th, after the market closes. A conference call has been scheduled to discuss this information on Thursday, October 30th, at 9:00 a.m. ET.
CRL: 64.43 (+1.27)
Shares of CRL Up 10.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 19, 11:18AM CDT
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on June 5th, 2014 at $55.08. In approximately 4 months, Charles River Laboratories has returned 10.89% as of today's recent price of $61.08.
CRL: 64.43 (+1.27)
Shares of CRL Up 9.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 12, 10:06AM CDT
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on June 5th, 2014 at $55.08. In approximately 3 months, Charles River Laboratories has returned 9.82% as of today's recent price of $60.49.
CRL: 64.43 (+1.27)
